

IBC Meeting Minutes

Cleveland Clinic Florida Research and Innovation Center

Date: October 16 th , 2025	Location: Zoom
IBC Member Attendance: <div style="display: flex; flex-wrap: wrap;"> <div style="width: 33%;"> <input checked="" type="checkbox"/> McDonald, Christine (IBC Chair) <input checked="" type="checkbox"/> Champer, Dylan (BSO/Acting Chair) <input checked="" type="checkbox"/> Tavakoli, Sara <input type="checkbox"/> Stolley, Michael </div> <div style="width: 33%;"> <input checked="" type="checkbox"/> Li, Kun <input checked="" type="checkbox"/> Hajjar, Adeline <input checked="" type="checkbox"/> O'Connor, Christine </div> <div style="width: 33%;"> <input checked="" type="checkbox"/> Such, Kimberly <input type="checkbox"/> Judd, Leslie <input type="checkbox"/> Doud, Melissa </div> </div> <p><i>Guests: Amanda Dragan*, Anthony Santilli*, Anna Rietsch*, Jennifer Veillette*</i></p> <p><i>*Cleveland Clinic Main Campus</i></p>	
Call To Order: 2:32 pm	Adjourn: 2:51 pm

I. Review of September 18th , 2025 Meeting Minutes

Committee Comments: None			
Motion: Approval	For: 6	Against: 0	Abstain: 1

II. Administrative Business

- a. Committee presented with personnel additions.

III. Non-Clinical Research:

a. Amendments:

Basic Research Amendment # 1	Protocol ID: FLIBC021	PI: Sautto	Biosafety Level: BSL-1, BSL-2+, ABSL-2	NIH Cat.: III-E, III-D-1-a, III- D-2-a
Project Titles: Influenza and hepatitis C virus neutralization				
Associated Grant Numbers: Non-NIH Funding				
Summary of Approved Items:				

Propagation and generation of Influenza A & B viral strains and recombinant Hepatitis C Virus, virus like particles / pseudoparticles; Transduction of tissue culture cells; Generation of phagemid and retroviral particles, transduction of cells in-vitro, administration of Influenza A & B viral strains, plasmid DNA, <i>in vivo</i> administration of recombinant proteins; Recombinant and Non-Recombinant Respiratory syncytial virus and human metapneumovirus for in vitro and <i>in vivo</i> experiments; Propagation of SARS-CoV-2, <i>in vivo</i> administration of SARS-CoV-2, human-derived materials.					
Requested Additions/Changes: <ul style="list-style-type: none"> Increase in viral titer administration, addition of new RSV and HMPV strains, procedural change. 					
Function/Nature of Recombinant Genes to be Expressed: <input type="checkbox"/> N/A <input type="checkbox"/> Oncogene <input type="checkbox"/> Tumor Suppressor Gene <input type="checkbox"/> Structural <input checked="" type="checkbox"/> Signaling <input type="checkbox"/> Antimicrobial <input type="checkbox"/> Immunomodulatory <input type="checkbox"/> Toxin <input type="checkbox"/> Antibiotic Resistance <input type="checkbox"/> Reporters <input type="checkbox"/> Other					
Species of Recombinant Genes to be Expressed: <input type="checkbox"/> N/A <input type="checkbox"/> Human <input type="checkbox"/> Murine <input type="checkbox"/> Rat <input type="checkbox"/> Bacterial <input checked="" type="checkbox"/> Viral <input type="checkbox"/> Other					
Risk Assessment Discussion: <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No			Facilities, Procedures, and Safety Practices Reviewed (Y/N): <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		
Discussion/Required Modifications: <ul style="list-style-type: none"> Clarify source of material Administrative edits 					
PI/Supervisor Training (Y/N): <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No			Handler Training (Y/N): <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		
Motion: Approved with Administrative Revisions	For: 7	Against: 0	Abstain: 0	Recuse: 0	Not Present: 0

Basic Research Amendment # 2	Protocol ID: FLIBC016	PI: Li	Biosafety Level: BSL-2, BSL-2+	NIH Cat.: III-D-1-a, III-D-2-a, III-D-3-a III-D-4-b, III-E
Project Titles: Investigating Viral Entry Mechanisms and Evaluating Antiviral Compounds.				
Associated Grant Numbers: Non-NIH Funding				
Summary of Approved Items: Acquisition and propagation of SARS-CoV-2, <i>in vivo</i> administration; Generation of recombinant Vesicular Stomatitis Virus (VSV), generation of SARS-CoV-2 and MERS-CoV				

pseudovirus particles in culture; infection of cell lines, <i>in vivo</i> administration. Transfection of cell lines; Human-Derived Materials.					
Requested Additions/Changes: <ul style="list-style-type: none"> Addition of recombinant strain of SARS-CoV-2 					
Function/Nature of Recombinant Genes to be Expressed: <input type="checkbox"/> N/A <input type="checkbox"/> Oncogene <input type="checkbox"/> Tumor Suppressor Gene <input type="checkbox"/> Structural <input checked="" type="checkbox"/> Signaling <input type="checkbox"/> Antimicrobial <input type="checkbox"/> Immunomodulatory <input type="checkbox"/> Toxin <input type="checkbox"/> Antibiotic Resistance <input type="checkbox"/> Reporters <input type="checkbox"/> Other					
Species of Recombinant Genes to be Expressed: <input type="checkbox"/> N/A <input type="checkbox"/> Human <input type="checkbox"/> Murine <input type="checkbox"/> Rat <input type="checkbox"/> Bacterial <input checked="" type="checkbox"/> Viral <input type="checkbox"/> Other					
Risk Assessment Discussion: <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No			Facilities, Procedures, and Safety Practices Reviewed (Y/N): <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		
Discussion/Required Modifications: <ul style="list-style-type: none"> Administrative edits 					
PI/Supervisor Training (Y/N): <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No			Handler Training (Y/N): <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		
Motion: Approved with Administrative Revisions	For: 6	Against: 0	Abstain: 1	Recuse: 0	Not Present: 0

IV. Updated SOPs:

SOP a: Policy for HPAI Quarantine	Comments: None			
Motion: Approved	For: 7	Against: 0	Abstain: 0	Recuse: 0

SOP b: L.SOP.400.08 - BSL-3 Training Procedures	Comments: None			
Motion: Approved	For: 7	Against: 0	Abstain: 0	Recuse: 0

SOP c: L.SOP.302.03 - Biological Waste Disposal	Comments: None			
Motion: Approved	For: 7	Against: 0	Abstain: 0	Recuse: 0

SOP d: L.SOP.201.04 - Autoclave – Safe Use and Validation	Comments: None			
Motion:	For:	Against:	Abstain:	Recuse:

Approved	7	0	0	0
----------	---	---	---	---

SOP e: L.PLAN.400.11 BSL-3 Biosafety Plan	Comments: None			
Motion: Approved	For: 7	Against: 0	Abstain: 0	Recuse: 0